Update: TG4010 data met expectations
Data from the Phase II stage of the TIME trial presented at the ESMO conference confirm the potential of TG4010 in non-small cell lung cancer (NSCLC). Discussions with regulators are ongoing, which should result in the Phase III stage of the trial starting in Q115. We also remain optimistic that Transgene will find a new partner for TG4010, because of the survival benefit observed so far and the prospect of an even greater benefit if combined with one of the promising immunotherapies (eg nivolumab) in development for NSCLC. We increase our valuation by €20m to €415m.Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.